The Effectiveness of
Liraglutide
Nigella sativa
appetite
body weight
ginger
Journal
Vascular health and risk management
ISSN: 1178-2048
Titre abrégé: Vasc Health Risk Manag
Pays: New Zealand
ID NLM: 101273479
Informations de publication
Date de publication:
2023
2023
Historique:
received:
04
11
2022
accepted:
05
01
2023
entrez:
17
1
2023
pubmed:
18
1
2023
medline:
19
1
2023
Statut:
epublish
Résumé
Obesity is a global pandemic that is associated with high morbidity and mortality. Natural herbs are commonly used for weight reduction and appetite suppression. Therefore, we aim to investigate the role and mechanism of This experimental study was performed at Imam Abdulrahman Bin Faisal University. Twenty-five female rats were distributed into 5 groups: NS (oral 1000mg/kg), Ginger (500 mg/kg), NS-ginger (both interventions), a positive control (intraperitoneal 50 μg/kg Liraglutide), and a negative control. Each intervention was given for 9 weeks. Food intake and body weight were assessed weekly. Serum lipid profile and peptides involved in appetite control (cholecystokinin (CCK), glucagon-like peptide 1(GLP-1), gastric inhibitory polypeptide (GIP), ghrelin, peptide YY, and orexin) were assayed at the end of the experiment. None of the interventions showed a statistically significant difference regarding food consumption or weight gain (p > 0.05). However, the three interventions significantly reduced total cholesterol (TC), NS and NS-ginger significantly increased HDL, NS increased ghrelin and ginger increased orexin. The present dose and duration of NS, ginger, or in combination did not demonstrate a significant change in body weight or food consumption in comparison to the negative or positive controls. However, NS or ginger has improved the lipid profile by reducing TC and increasing HDL. In addition, NS or ginger can influence some of the peptides involved in appetite regulation such as the increase in ghrelin induced by NS and the reduction of orexin induced by ginger. We believe that these latter effects are novel and might indicate a promising effect of these natural products on appetite regulation.
Sections du résumé
Background
UNASSIGNED
Obesity is a global pandemic that is associated with high morbidity and mortality. Natural herbs are commonly used for weight reduction and appetite suppression. Therefore, we aim to investigate the role and mechanism of
Methods
UNASSIGNED
This experimental study was performed at Imam Abdulrahman Bin Faisal University. Twenty-five female rats were distributed into 5 groups: NS (oral 1000mg/kg), Ginger (500 mg/kg), NS-ginger (both interventions), a positive control (intraperitoneal 50 μg/kg Liraglutide), and a negative control. Each intervention was given for 9 weeks. Food intake and body weight were assessed weekly. Serum lipid profile and peptides involved in appetite control (cholecystokinin (CCK), glucagon-like peptide 1(GLP-1), gastric inhibitory polypeptide (GIP), ghrelin, peptide YY, and orexin) were assayed at the end of the experiment.
Results
UNASSIGNED
None of the interventions showed a statistically significant difference regarding food consumption or weight gain (p > 0.05). However, the three interventions significantly reduced total cholesterol (TC), NS and NS-ginger significantly increased HDL, NS increased ghrelin and ginger increased orexin.
Conclusion
UNASSIGNED
The present dose and duration of NS, ginger, or in combination did not demonstrate a significant change in body weight or food consumption in comparison to the negative or positive controls. However, NS or ginger has improved the lipid profile by reducing TC and increasing HDL. In addition, NS or ginger can influence some of the peptides involved in appetite regulation such as the increase in ghrelin induced by NS and the reduction of orexin induced by ginger. We believe that these latter effects are novel and might indicate a promising effect of these natural products on appetite regulation.
Identifiants
pubmed: 36647392
doi: 10.2147/VHRM.S396295
pii: 396295
pmc: PMC9840438
doi:
Substances chimiques
Appetite Depressants
0
Ghrelin
0
Glucagon-Like Peptide 1
89750-14-1
Lipids
0
Orexins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-11Informations de copyright
© 2023 Al Asoom et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Complement Ther Med. 2021 Mar;57:102653
pubmed: 33370571
J Res Med Sci. 2016 Jan 28;21:3
pubmed: 27904549
J Ethnopharmacol. 2004 Oct;94(2-3):251-9
pubmed: 15325727
J Ayub Med Coll Abbottabad. 2005 Apr-Jun;17(2):72-4
pubmed: 16092657
Medicines (Basel). 2019 Sep 09;6(3):
pubmed: 31505825
Phytother Res. 2018 Apr;32(4):577-585
pubmed: 29193411
Endocrine. 2019 Aug;65(2):286-294
pubmed: 31152309
Ann N Y Acad Sci. 2017 Jun;1398(1):83-98
pubmed: 28505392
Am J Physiol Endocrinol Metab. 2005 Jul;289(1):E15-22
pubmed: 15701677
Ann Saudi Med. 2017 Jan-Feb;37(1):64-71
pubmed: 28151459
Obesity (Silver Spring). 2011 Jul;19(7):1342-9
pubmed: 21415845
Ann Saudi Med. 2017 Jan-Feb;37(1):56-63
pubmed: 28151458
Obes Sci Pract. 2017 Mar;3(1):3-14
pubmed: 28392927
J Nutr Biochem. 2019 Aug;70:105-115
pubmed: 31200315
Plant Pathol J. 2020 Dec 1;36(6):515-535
pubmed: 33312089
Indian J Physiol Pharmacol. 2010 Oct-Dec;54(4):344-54
pubmed: 21675032
Am Fam Physician. 2016 Jul 15;94(2):161-6
pubmed: 27419334
Food Funct. 2015 Jun;6(6):2041-8
pubmed: 26029855
Molecules. 2022 Jun 16;27(12):
pubmed: 35745000
Diabetes Obes Metab. 2019 Apr;21(4):866-875
pubmed: 30456866
Physiol Behav. 1997 Jul;62(1):105-11
pubmed: 9226349
Phytother Res. 2003 Apr;17(4):299-305
pubmed: 12722128
Phytother Res. 2021 Jul;35(7):3747-3755
pubmed: 34142392
Horm Metab Res. 2004 Nov-Dec;36(11-12):846-51
pubmed: 15655718
J Food Sci. 2022 Jul;87(7):3307-3317
pubmed: 35708209
Annu Rev Physiol. 2017 Feb 10;79:401-423
pubmed: 27912679
Saudi J Med Med Sci. 2017 May-Aug;5(2):149-154
pubmed: 30787774
J Ethnopharmacol. 2009 Jan 30;121(3):419-24
pubmed: 19061948
Physiol Behav. 2017 Aug 1;177:4-12
pubmed: 28366815
Exp Physiol. 2004 Sep;89(5):507-16
pubmed: 15184357
Curr Atheroscler Rep. 2021 Aug 4;23(10):59
pubmed: 34345933
Neuron. 2017 Aug 16;95(4):757-778
pubmed: 28817798
Front Endocrinol (Lausanne). 2021 Sep 06;12:706978
pubmed: 34552557
J Diabetes Complications. 2021 Jul;35(7):107947
pubmed: 34006388
Cardiovasc Toxicol. 2014 Sep;14(3):243-50
pubmed: 24497112
J Ethnopharmacol. 2018 Jun 12;219:173-181
pubmed: 29559374
Front Public Health. 2022 May 10;10:863765
pubmed: 35619826
BMC Complement Altern Med. 2017 Jun 13;17(1):308
pubmed: 28610577
Sci Rep. 2019 Jun 11;9(1):8447
pubmed: 31186439
Obesity (Silver Spring). 2019 Dec;27(12):2005-2010
pubmed: 31746553
Nurs Clin North Am. 2021 Dec;56(4):449-464
pubmed: 34749887
Obes Rev. 2022 Jul;23(7):e13448
pubmed: 35338558
Int J Health Sci (Qassim). 2020 Nov-Dec;14(6):1-3
pubmed: 33192225
Evid Based Complement Alternat Med. 2021 Apr 09;2021:5553022
pubmed: 34055008
J Integr Med. 2014 Jan;12(1):66
pubmed: 24461597
Foods. 2020 Jan 02;9(1):
pubmed: 31906567
Int J Biol Sci. 2008 Apr 29;4(3):126-32
pubmed: 18449357
Curr Opin Clin Nutr Metab Care. 2013 Nov;16(6):619-24
pubmed: 24100676
Curr Hypertens Rep. 2017 Apr;19(4):34
pubmed: 28353077
Eur Rev Med Pharmacol Sci. 2013 Jan;17(1):75-83
pubmed: 23329526
Consult Pharm. 2016 Dec 1;31(12):685-697
pubmed: 28074747
Phytomedicine. 2002 Jan;9(1):69-74
pubmed: 11924767
J Physiol Pharmacol. 2005 Dec;56 Suppl 6:5-25
pubmed: 16340035
J Pharmacol Pharmacother. 2013 Oct;4(4):303-6
pubmed: 24250214
Horm Metab Res. 2008 Jan;40(1):38-43
pubmed: 18176912